Christopher Michael Bull
Plus aucun poste en cours
Profil
Christopher Michael Bull served as the Independent Non-Executive Chairman at African Dawn Capital Ltd.
from 2015 to 2015.
He also worked as a Director at Oxyrane UK Ltd.
Additionally, he pursued an undergraduate degree at the University of KwaZulu-Natal.
Anciens postes connus de Christopher Michael Bull
Sociétés | Poste | Fin |
---|---|---|
AFRICAN DAWN CAPITAL LIMITED | Président | 12/06/2015 |
Oxyrane UK Ltd.
Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Directeur/Membre du Conseil | - |
Formation de Christopher Michael Bull
University of KwaZulu-Natal | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
AFRICAN DAWN CAPITAL LIMITED | Finance |
Entreprise privées | 1 |
---|---|
Oxyrane UK Ltd.
Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Health Technology |